Presymptomatic D-CAA (n = 11) | Young controls (n = 16) | Symptomatic D-CAA (n = 24) | Older controls (n = 24) | P-value/adjusted p-value§, Presymp vs YC | B* (95% CI) | P-value/adjusted p-value§, Symp vs OC | B** (95% CI) | P-value/adjusted p-value§ Presymp vs Symp | B*** (95% CI) | |
---|---|---|---|---|---|---|---|---|---|---|
Age (years) | 35 [24–47] | 37 [34–45] | 55 [51–60] | 58 [53–63] | 0.61a | – | 0.079a | – | < 0.001a | – |
Sex, F/M (n) | 8/3 | 11/5 | 11/13 | 10/14 | 0.82b | – | 0.78b | – | 0.14b | – |
MMSE | 30 [30–30] | 29 [29, 30] | 29 [27–30]; n = 23 | 29 [29, 30] | 0.58a | – | 0.03a | – | 0.005a | – |
Plasma | ||||||||||
Aβ38 (pg/ml) | 12.3 [10.3–13.0] | 17.2 [13.9–18.9] | 12.1 [10.1–13.8] | 16.1 [14.1–19.9] | < 0.001a/ < 0.001§ | − 5.22 (− 7.81 to − 2.63) | < 0.001a/ < 0.001§ | − 4.81 (− 7.04 to − 2.58) | 0.96a/0.17§ | 0.55 (− 2.36 to 3.46) |
Aβ40 (pg/ml) | 132 ± 37 | 164 ± 28 | 132 ± 30 | 156 ± 27 | 0.019c/0.009§ | − 35.56 (− 61.15 to − 9.97) | 0.005c/0.01§ | − 22.96 (− 40.31 to − 5.61) | 0.98c/0.70§ | − 0.35 (− 24.18 to 23.48) |
Aβ42 (pg/ml) | 20 ± 7 | 28 ± 4 | 21 ± 4 | 27 ± 5 | < 0.001c/ < 0.001§ | − 8.96 (− 13.11 to − 4.82) | 0.001c/ < 0.001§ | − 5.38 (− 8.13 to − 2.64) | 0.38c/0.07§ | 1.70 (− 2.17 to 5.56) |
CSF | ||||||||||
Aβ40 (ng/ml) | 3.17 [2.78–3.75]; n = 4 | 3.72 [3.33–4.68]; n = 5 | 1.36 [1.25–1.54]; n = 9 | 4.49 [1.41–5.23]†; n = 3 | 0.29a | – | 0.036a | – | 0.003a | – |
Aβ42 (pg/ml) | 512 [414–601]; n = 4 | 1008 [847–1120]; n = 5 | 298 [251–357]; n = 9 | 1022 [785–1342]†; n = 3 | 0.016a | – | 0.009a– | – | 0.006a | – |